
Why It’s Time to Re-evaluate Your Old Fill/Finish CDMO
With the costs to produce and package a drug climbing, companies are justifiably risk averse when it comes to changing fill/finish CDMOs. Why would you try a new partner company
With the costs to produce and package a drug climbing, companies are justifiably risk averse when it comes to changing fill/finish CDMOs. Why would you try a new partner company
I hope you are doing well and staying healthy in this challenging time of unprecedented change. I want to share with you how Argonaut is serving clients in these unpredictable
The COVID-19 pandemic has added complexity to global shipping logistics. There is general market disruption in industry delivery. Airline freight rates are rising as cargo capacity falls over 29% compared to 2019.
Advanced Facility Readies to Combat COVID-19 (Carlsbad, CA) March 23, 2020 – Argonaut Manufacturing Services announced today it has immediate availability for aseptic drug product manufacturing fill/finish service. Argonaut will
The global COVID-19 outbreak has served as an important lesson for companies worldwide on the importance of supply chain integrity. Factory shutdowns across China are wreaking havoc on unprepared companies
CARLSBAD, CA, Mar. 3, 2020 Open Biopharma Research and Training Institute and Argonaut Manufacturing Services announced today their selection as a Biotech Ecosystem Tour for the 2020 BIO International Convention.
Partnership leverages their individual strengths to achieve high quality, reliable drug product manufacturing. February 25, 2020 – Argonaut Manufacturing Services, a contract development and manufacturing organization (CDMO) for biopharmaceuticals, and
DURHAM, February 24, 2020 — BioSkryb, Inc., a developer of genomic amplification technologies that deliver higher coverage and fidelity for gene sequencing, today announced that it is partnering with Argonaut
Comparing competing proposals is the final step in selecting your biotech contract manufacturing organization (CMO). While it may sound straightforward, due to a lack of industry standardization proposals can vary significantly
Most research and development teams seeking to construct ambient products will encounter the challenges of protein lyophilization. A primary obstacle is enzyme and antibody instability outside of native conditions, as